Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Previous study revealed that elevated expression of
RAB27B
in tissues is correlated with hepatocellular carcinoma (HCC) progression; however, the mechanisms involved in promoting HCC development are still unclear. Moreover, HCC tissues are not readily obtained during routine diagnosis. Therefore, to further explore its potential value in early diagnosis, we examined
RAB27B
expression in patient sera. First, the correlation between serum
RAB27B
expression and survival, as well as TNM and Barcelona Clinic
Liver Cancer
stages, were evaluated in patients with HCC. Second, lentiviral vector plasmids carrying interference sequences and plasmids harboring the complete open reading frame of
RAB27B
were designed to knockdown or overexpress
RAB27B
in BEL7402 or HuH-7 cells to determine its biological function. Compared with healthy controls and patients with chronic hepatitis B infection, serum
RAB27B
was significantly increased in patients with HCC. After down-regulating expression of
RAB27B
, the proliferation of BEL7402 cells was remarkably inhibited both
in vitro
and
in vivo
. Additionally, activation of the PI3K/AKT pathway was significantly diminished. Moreover, cell cycle progression of the knockdown cells was notably arrested in the G1/S phase, and upregulation of p21 contributed to this effect. Restoration experiments to recover
RAB27B
expression revealed opposing results. These findings indicated
RAB27B
might regulate cell cycle through the PI3K/AKT/p21 pathway by releasing cytokines via exocytosis, thereby modulating the proliferation of HCC cells.
RAB27B
could potentially be a valuable serum biomarker for the early diagnosis of, and a therapeutic target in, HCC.
...
PMID:Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling. 2897 51